Island Pharmaceuticals Limited (ASX:ILA)

25.5¢

right-arrow Created with Sketch. -0.005 (-1.92%)
MCAP $21.12M
Last trade 15.54pm 20/01/2022 20mins delayed

Latest Announcements

04/01/2022 Price SensitivePSILAIsland Pharmaceuticals Limited
373
MCap
25/11/2021ILAIsland Pharmaceuticals Limited
1,944
MCap
18/11/2021ILAIsland Pharmaceuticals Limited
199
MCap
18/11/2021ILAIsland Pharmaceuticals Limited
126
MCap
18/11/2021ILAIsland Pharmaceuticals Limited
140
MCap
18/11/2021ILAIsland Pharmaceuticals Limited
125
MCap
18/11/2021ILAIsland Pharmaceuticals Limited
138
MCap
17/11/2021ILAIsland Pharmaceuticals Limited
190
MCap

Company Overview

Island Pharmaceuticals Ltd is an Australia-based drug research and repurposing company. The Company focuses on developing preventative or therapeutic drugs for viral infections. Its lead product candidate ISLA-101, is a drug developed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Its ISLA-101 is an antiviral oral drug to treat mosquito-borne viruses and is in Phase II of clinical program.

ILA in the news

Island Pharmaceuticals (ASX:ILA) executes PEACH clinical study CRO agreement

Island Pharmaceuticals (ILA) has brought on ICON Government and Public Health Solutions…

Island Pharmaceuticals (ASX:ILA) signs contract for dengue fever trial

Island Pharmaceuticals (ILA) signs a contract for a clinical trial site for…

Island Pharmaceuticals (ASX:ILA) signs new API deal with Curia

Island Pharmaceuticals (ILA) enters one-off purchase deal with Curia, Inc.The deal covers…

Island Pharmaceuticals (ASX:ILA) granted Australian patent for Dengue treatment

Island Pharmaceuticals (ILA) is granted an Australian patent for its method of…

Search Previous Announcements